Metraipolis › archive › dc_69791280ca37

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study — Europe PMC PMID:42310849

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42310849
DOI
10.1002/ana.78286
License (as archived)
solo-consultazione
Archived
2026-10-19T09:15:52.664Z
SHA-256 of the archived text
5894e0725fe28c678566c3d290794648727d66e5cd141b38e97e4fb426bf9960
Stable URL of this page
https://metraipolis.com/documento/dc_69791280ca37

How to cite

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study — Europe PMC PMID:42310849 — Europe PMC (en), https://europepmc.org/article/MED/42310849 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_69791280ca37 (Metraipolis archive dc_69791280ca37, sha256 5894e0725fe28c678566c3d290794648727d66e5cd141b38e97e4fb426bf9960)
BibTeX
@misc{dc69791280ca37,
  title = {Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study — Europe PMC PMID:42310849},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42310849},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_69791280ca37; sha256 5894e0725fe28c678566c3d290794648727d66e5cd141b38e97e4fb426bf9960},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42310849. Agents can read the archived copy with the MCP tool read_document.